|
41 |
The Burden of Survivorship on Hematological Patients—Long-Term Analysis of Toxicities after Total Body Irradiation and Allogeneic Stem Cell Transplantation
Oertel, Michael. - Münster : Universitäts- und Landesbibliothek Münster, 2021
|
|
|
42 |
Magnesium levels and outcome after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia
Enthalten in Annals of hematology 19.12.2020: 1-8
|
|
|
|
43 |
Sequential therapy with inotuzumab ozogamicin, CD19 CAR T cells, and blinatumomab in an elderly patient with relapsed acute lymphoblastic leukemia
Enthalten in Annals of hematology 22.8.2020: 1-3
|
|
|
|
44 |
Donor selection for a second allogeneic stem cell transplantation in AML patients relapsing after a first transplant: a study of the acute leukemia working party of EBMT
Shimoni, Avichai. - Freiburg : Universität, 2019
|
|
|
|
45 |
Haploidentical versus unrelated allogeneic stem cell transplantation for relapsed/refractory acute myeloid leukemia: a report on 1578 patients from the Acute Leukemia Working Party of the EBMT
Brissot, Eolia. - Freiburg : Universität, 2019
|
|
|
|
46 |
Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia
Schetelig, Johannes. - Freiburg : Universität, 2019
|
|
|
|
47 |
Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation
Gagelmann, Nico. - Freiburg : Universität, 2019
|
|
|
|
48 |
Predicted Indirectly ReCognizable HLA Epitopes (PIRCHE) Are Associated with Poorer Outcome after Single Mismatch Unrelated Donor Stem Cell Transplantation: A Study of the Cooperative Transplant Study Group (KTS) of the German Group for Bone Marrow and Stem Cell Transplantation (DAG-KBT)
Enthalten in Transfusion medicine and hemotherapy Bd. 46, 2019, Nr. 5: 370-375
|
|
|
|
49 |
The neuropeptide receptor calcitonin receptor-like (CALCRL) is a potential therapeutic target in acute myeloid leukemia
Enthalten in Leukemia 10.6.2019: 1-12
|
|
|
|
50 |
Phase II clinical trial of pazopanib in patients with acute myeloid leukemia (AML), relapsed or refractory or at initial diagnosis without an intensive treatment option (PazoAML)
Enthalten in Annals of hematology 21.3.2019: 1-9
|
|
Administration
